p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5845-5849

  Jones, J Shawn ^a   Chi, Xuedong ^a   Gu, Xiangjun ^a   Lynch, Patrick M ^a   Amos, Christopher I ^a,b   Frazier, Marsha L ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BREAST CANCER; CAUCASIAN; COLORECTAL CANCER; ENVIRONMENTAL FACTOR; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MOUTH CANCER; MUTATION; NASOPHARYNX CANCER; ONSET AGE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, P53; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; RISK FACTORS;

EID: 4444324188     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0590     Document Type: Article

References (34)

1. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science (Wash. DC) 1993;260(5109):812-6.
2. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75(6):1215-25.
3. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75(5):1027-38.
4. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113(4):1146-58.
5. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (Lond.) 1994;368(6468):258-61.
6. Ichikawa Y, Tsunoda H, Takano K, Oki A, Yoshikawa H. Microsatellite instability and immunohistochemical analysis of MLH1 and MSH2 in normal endometrium, endometrial hyperplasia and endometrial cancer from a hereditary nonpolyposis colorectal cancer patient. Jpn J Clin Oncol 2002;32(3):110-2.
7. Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997;74(5):551-5.
8. Tomoda H, Baba H, Taketomi A, Kohnoe S, Seo Y, Saito T. Second primary extracolonic cancers in Japanese hereditary nonpolyposis colorectal cancer. Oncol Rep 1998;5(1):143-5.
9. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer (Phila.) 1993;71(3):677-85.
10. Xu H, el Gewely MR. p53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev 2001;7:131-64.
11. Roy B, Beamon J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994;14(12):7805-15.
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science (Wash. DC) 1991;253(5015):49-53.
13. Liu MC, Gelmann EP. p53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002;29(3):246-57.
14. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19(2):1092-100.
15. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (Lond.) 1998;393(6682):229-34.
16. Frazier ML, O'Donnell FT, Kong S, et al. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 2001;61(4):1269-71.
17. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60(2):249-52.
18. Heinen CD, Schmutte C, Fishel R. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol Ther 2002;1(5):477-85.
19. Zhang H, Richards B, Wilson T, et al. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 1999;59(13):3021-7.
20. Brieger A, Trojan J, Raedle J, Plotz G, Zeuzem S. Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants. Gut 2002;51(5):677-84.
21. 6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 2004;23(2):359-67.
22. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. p53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 109(1-2):25-34, 2001.
23. Burmer GC, Crispin DA, Kolli VR, et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun 1991;3(6):167-72.
24. Cleves M. sg110: Hardy-Weinberg equilibrium test and allele frequency estimation. Stata Technical Bulletin 1999;48:34-7. Reprinted in Stata Technical Bulletin Reprints 1999;8:280-4.
25. Cleves M. sg110: Hardy-Weinberg equilibrium test and allele frequency estimation. Stata Technical Bulletin 1999;48:34-7. Reprinted in Stata Technical Bulletin Reprints 1999;8:280-4.
26. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84(408):1074-8.
27. Kraft P, Thomas DC. Bias and efficiency in family-based gene-characterization studies: conditional, prospective, retrospective, and joint likelihoods. Am J Hum Genet 2000;66(3):1119-31.
28. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 2000;9(10): 1037-42.
29. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst (Bethesda) 2002;94(9):681-90.
30. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis (Lond.) 1995;16(9):2205-8.
31. Tsai MH, Lin CD, Hsieh YY, et al. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 2002;112(1):116-9.
32. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183(2):123-30.
33. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002;179(2):175-83.
34. Zhang ZW, Newcomb P, Hollowood A, et al. Age-associated Increase of codon 72 arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003;9(6):2151-6.